

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 December 2005 (08.12.2005)

PCT

(10) International Publication Number
WO 2005/115369 A2

(51) International Patent Classification⁷: **A61K 31/192**,
31/451, A61P 1/00, 1/16, 3/00, 15/00, 37/00

(74) Agents: **WOOD, David, J.** et al.; Pfizer Research and
Development, Ramsgate Road, Sandwich, Kent CT13 9NJ
(GB).

(21) International Application Number:
PCT/IB2005/001501

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 13 May 2005 (13.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/574,136 25 May 2004 (25.05.2004) US

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **PFIZER
PRODUCTS INC.** [US/US]; Eastern Point Road, Groton,
CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **GOETZE, Leopold,**
Franz [DE/GB]; Pfizer Global Research and Develop-
ment, Ramsgate Road, Sandwich, Kent CT19 9NJ (GB).
KEHRLI, Marcus, Eugene, Jr [US/US]; Pfizer Global
Research and Development, European Pharma Patents
Department, Ramsgate Road, Sandwich, Kent CT19 9NJ
(GB). **RICKETTS, Anthony, Paul** [GB/US]; Pfizer Inc.,
Eastern Point Road, Groton, CT 06340 (US). **TAUBE,**
Patrick, Carl [US/US]; Pfizer Inc., 5300 North 28th
Street, Richland, Michigan 49083 (US).

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: NEW USE

(57) Abstract: The use of a PPAR agonist in the manufacture of a medicament to increase ruminant serum glucose concentra-
tions, and preferably, the use for the palliative, prophylactic or curative treatment of ruminant disease associated with reduced serum
glucose concentration. The ruminant disease associated with reduced serum glucose concentration includes fatty liver syndrome,
dystocia, immune dysfunction, impaired immune function, toxification, primary ketosis, secondary ketosis, downer cow syndrome,
indigestion, inappetence, retained placenta, displaced abomasum, mastitis, (endo-)metritis, infertility, low fertility, lameness, suba-
cute rumen acidosis and inadequate nutrient intake associated with stress e.g. heat, poor housing, overcrowding, shipping, dominance
or illness.



WO 2005/115369 A2